Cargando…
Antithrombin III is probably not a suitable biomarker for diagnosis of primary central nervous system lymphoma
Antithrombin III (AT III) in cerebrospinal fluid (CSF) has been suggested to have high specificity and sensitivity in separating primary central nervous system (CNS) lymphoma from other neurological conditions. We measured with ELISA CSF and serum AT III and albumin levels in 12 lymphoma patients wi...
Autores principales: | Kuusisto, Milla Elvi Linnea, Haapasaari, Kirsi-Maria, Remes, Anne Marja, Bloigu, Risto, Karihtala, Peeter, Turpeenniemi-Hujanen, Taina, Kuittinen, Outi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4432105/ https://www.ncbi.nlm.nih.gov/pubmed/25697593 http://dx.doi.org/10.1007/s00277-015-2334-y |
Ejemplares similares
-
Nuclear factor erythroid 2-related factors 1 and 2 are able to define the worst prognosis group among high-risk diffuse large B cell lymphomas treated with R-CHOEP
por: Kari, Esa, et al.
Publicado: (2019) -
Impact of central nervous system (CNS) prophylaxis on the incidence of CNS relapse in patients with high-risk diffuse large B cell/follicular grade 3B lymphoma
por: Kuitunen, Hanne, et al.
Publicado: (2020) -
Oxidative stress and redox state-regulating enzymes have prognostic relevance in diffuse large B-cell lymphoma
por: Peroja, Pekka, et al.
Publicado: (2012) -
Integrin alpha 10, CD44, PTEN, cadherin-11 and lactoferrin expressions are potential biomarkers for selecting patients in need of central nervous system prophylaxis in diffuse large B-cell lymphoma
por: Lemma, Siria A, et al.
Publicado: (2017) -
Mutation of TP53, translocation analysis and immunohistochemical expression of MYC, BCL-2 and BCL-6 in patients with DLBCL treated with R-CHOP
por: Peroja, Pekka, et al.
Publicado: (2018)